Benzinga | Apr 29, 2021 07:37AM EDT

Applied Genetic Technologies Corporation To Present Data At Association For Research In Vision And Ophthalmology 2021 Virtual Annual Meeting Mat 3 And May 6

Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that data from the ongoing X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM) clinical trials will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Annual Meeting. Paul Yang, MD, PhD, will present interim data from the XLRP Phase 1/2 trial and Mark Pennesi, MD, PhD, will present interim data from the ACHM Phase 1/2 clinical trials.

Details of XLRP Presentation:

Session Title: Six-Month Findings from a Phase 1/2 Clinical Study of Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa Show Clinically Meaningful Improvement in Macular Sensitivity



Lead Presenter: Paul Yang, MD, PhD, Casey Eye Institute, Oregon Health & Science University, Assistant Professor, XLRP Investigator

Session Date: Monday, May 3, 4:30-6:00 PM EDT

Details of ACHM Presentation

Session Title: 12-Month Findings from Two Phase 1/2 Clinical Studies of Subretinal Gene Therapy Drugs for Achromatopsia

Lead Presenter: Mark Pennesi, MD, PhD, Casey Eye Institute, Oregon Health & Science University, Assistant Professor, ACHM Investigator

Session Date: Thursday, May 6, 5:15-6:45 PM EDT